Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Piaserico, S; Cazzaniga, S; Chimenti, S; Giannetti, A; Maccarone, M; Picardo, M; Peserico, A; Naldi, L; Psocare Study Group.
Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry.
J Am Acad Dermatol. 2014; 70(2):257-262
Doi: 10.1016/j.jaad.2013.10.019
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Study Group Members Med Uni Graz:
- Brunasso Vernetti Alexandra Maria
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event. We sought to assess the variables predicting the efficacy of the second TNF-alfa inhibitor in patients discontinuing the first TNF-alfa inhibitor. Data from all 5423 consecutive patients starting TNF-alfa inhibitor therapy for psoriasis between September 2005 and September 2010 who were included in the Italian Psocare registry were analyzed. In 105 patients who switched to a second TNF-alfa inhibitor who had complete follow-up data, 75% improvement in the Psoriasis Area Severity Index score (PASI 75) was reached by 29% after 16 weeks and by 45.6% after 24 weeks. Patients who switched because of secondary loss of efficacy (loss of initial PASI 75 response) or adverse events/intolerance were more likely to reach PASI 75 than those who switched as a result of primary inefficacy (PASI 75 never achieved) (hazard ratio 2.7, 95% confidence interval 1.3-5.5 vs hazard ratio 2.0, 95% confidence interval 1.0-3.9 and 1, respectively). There was a small number of patients with complete follow-up data. PASI 75 response in patients who switched from one anti-TNF-alfa agent to another was significantly reduced in patients who showed primary inefficacy of the first anti-TNF-alfa. Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Analysis of Variance -
- Antibodies, Monoclonal - administration & dosage
- Antibodies, Monoclonal, Humanized - administration & dosage
- Cohort Studies -
- Confidence Intervals -
- Dose-Response Relationship, Drug -
- Drug Administration Schedule -
- Female -
- Follow-Up Studies -
- Humans -
- Immunoglobulin G - administration & dosage
- Immunoglobulin G -
- Male -
- Middle Aged -
- Multivariate Analysis -
- Predictive Value of Tests -
- Proportional Hazards Models -
- Psoriasis - diagnosis
- Receptors, Tumor Necrosis Factor - administration & dosage
- Registries -
- Retrospective Studies -
- Risk Assessment -
- Severity of Illness Index -
- Treatment Outcome -
- Tumor Necrosis Factor-alpha - antagonists & inhibitors
- Young Adult -
- Find related publications in this database (Keywords)
- biologics
- efficacy
- primary inefficacy
- psoriasis
- secondary loss of efficacy
- switching
- tumor necrosis factor-alfa inhibitors